| 标题： | 肝细胞癌分子靶向药物临床应用中国专家共识 （2020版） |
| title： | Chinese expert consensus on clinical application of targeted therapy for hepatocellular carcinoma (2020) |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 治疗 |
| field： | Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 医生 |
| Guide users： | Doctor |
| 证据分级方法： | 证据级别 描述 Ia 证据源于对多项随机对照研究的Meta分析结果 Ib 证据源于至少一项设计良好的随机对照研究结果 IIa 证据源于至少一项设计良好的前瞻性非随机对照研究结果 IIb 证据源自至少一项设计良好的其他类型干预性临床研究结果 III 证据源于设计良好的非干预性研究，如描述性研究、相关性研究等 IV 证据源于专家委员会报告或权威专家的临床经验报道 |
| Evidence grading method： | IA evidence derived from Meta-analysis results of multiple randomized controlled studies IB evidence derived from at least one well-designed randomized controlled study IIA evidence derived from at least one well-designed prospective non-randomized controlled study IIB evidence derived from at least one well-designed other type of intervention clinical study III evidence derived from a well-designed non-intervention study, such as descriptive studies, Correlation Studies and other IV evidence from Expert Committee reports or authoritative clinical experience of experts reported |
| 制定单位： | 中国医师协会肝癌专业委员会 |
| Formulating unit： | Chinese Association of Liver Cancer |
| 注册时间： | 2022-03-06 |
| Registration time： | |
| 注册编号： | IPGRP-2022CN107 |
| Registration number： | |
| 指南制订的目的： | 规范分子靶向药物在肝细胞癌患者中的应用 |
| Purpose of the guideline： | To standard the application of molecular targeting drugs in patients with hepatocellular carcinoma(HCC) |
